{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-298535","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.888115+00:00","generated_at":"2026-06-21T09:31:07.099668+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aura Biosciences raises $86.7M in public offering of 7.7M shares at $12.00/share","bullets":["Net proceeds of ~$86.7M from 7.705M shares (including full overallotment) at $12.00 per share.","Proceeds to advance belzupacap sarotalocan for choroidal melanoma and NMIBC, plus platform and corporate.","Management expects cash runway to fund operations into 2025.","Offering closed Dec 5, 2022; underwriters led by SVB Securities, Cowen, Evercore."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-298535","json":"https://secwatch.observer/filing/0001193125-22-298535.json","markdown":"https://secwatch.observer/filing/0001193125-22-298535.md","text":"https://secwatch.observer/filing/0001193125-22-298535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522298535/0001193125-22-298535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522298535/d393902d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:31:07.099668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88e829beb411ac796ef7b9ee245bbecd8182c755","claim":"Aura Biosciences, Inc. entered into Underwriting Agreement with SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C valued at 6,700,000 shares of common stock at $12.00 per share, with option for additional 1,005,000 shares (effective 2022-11-30).","evidence_excerpt":"On November 30, 2022, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C, as representatives of the several underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 6,700,000 shares of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), to the Underwriters at a public offering price of $12.00 per share (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522298535/0001193125-22-298535-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C"},{"label":"Value","value":"6,700,000 shares of common stock at $12.00 per share, with option for additional 1,005,000 shares"},{"label":"Effective","value":"2022-11-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}